Taysha Gene Therapies, Inc. (TSHA)
Nasdaq: TSHA · Biological Products, (No Diagnostic Substances) · Dallas, TX · filing with the SEC since 2020
Who runs Taysha Gene Therapies, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Nolan Sean P.
Chief Executive Officer. First filing Sep 2020, latest Jan 27, 2026, 3 filings in all.
Officers reporting now
3
of 7 people with a filing in the last fifteen months
Directors reporting now
4
11 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | Sep 2020 | Jul 10, 2026 | 7 · $5.3M |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Sep 2020 | Feb 6, 2026 | 3 · $500,000 |
| Nolan Sean P. | Chief Executive Officer | Sep 2020 | Jan 27, 2026 | 2 · $800,000 |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Donenberg Phillip B. | director | Sep 2020 | Jun 2, 2026 | none |
| Long Alison S | director | Nov 2023 | Jun 2, 2026 | none |
| Sepp-Lorenzino Laura | director | Nov 2020 | Jun 2, 2026 | none |
| Stalfort John A III | director | Jun 2023 | Jun 2, 2026 | none |
Earlier names on the record6, newest filing first
Manning Paul B · director · last filing Jun 2025Session R.A. II · officer · last filing Jul 2023Reape Kathleen · director · last filing Jun 2023Astellas Pharma Inc. · 10% owner · last filing Oct 2022Audentes Therapeutics, Inc. · 10% owner · last filing Oct 2022Prasad Suyash · officer · last filing Jul 2022
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.